Greedy Insider
CBIO Insider Trades and Greediness Scores
CRESCENT BIOPHARMA, INC. (CBIO) insider trades: since Dec 4, 2025, Greedy Insider recorded 4 open-market buys and 16 sales on Form 4 from 8 insiders. The strongest recent filing scored 91 (Strong).
Who bought and who sold
Across the last 20 scoreable Form 4 transactions in CBIO, 4 were open-market purchases and 16 were sales. The table lists the most recent filings with each one's Greediness Score, so the structurally unusual trades are easy to spot first.
| Insider | Role | Type | Shares | Date | Score | ||
|---|---|---|---|---|---|---|---|
| Brumm Joshua T | CEO | Sell | 7837.0 | 130956.27 | 2026-09-18 | 79 | View |
| McNeill Jonathan | President | Sell | 3839.0 | 64149.69 | 2026-09-18 | 79 | View |
| Pinkas Jan | Chief Scientific Officer | Sell | 658.0 | 11778.2 | 2026-09-16 | 81 | View |
| Brumm Joshua T | CEO | Sell | 1610.0 | 28819.0 | 2026-09-16 | 74 | View |
| Lynch Ryan | See Remarks | Sell | 240.0 | 4296.0 | 2026-09-16 | 69 | View |
| Scalzo Richard William | CFO | Sell | 568.0 | 10167.2 | 2026-09-16 | 81 | View |
| Im Ellie Eunkyung | Chief Medical Officer | Sell | 623.0 | 11151.7 | 2026-09-16 | 81 | View |
| McNeill Jonathan | President | Sell | 731.0 | 13084.9 | 2026-09-16 | 74 | View |
| Bispham Barbara Harlin | See Remarks | Sell | 620.0 | 11098.0 | 2026-09-16 | 69 | View |
| Fairmount Funds Management LLC | 10% owner | Buy | 853450.0 | 12375025.0 | 2026-07-16 | 64 | View |
The strongest recent filing
Brumm Joshua T (CEO) sold 42,305 shares of CRESCENT BIOPHARMA, INC. on Jun 22, 2026, a filing that scored 91 (Strong). It scored Strong because a senior insider was trading and several insiders moved the same way within a week. The score describes the filing, not future returns. This is not investment advice.
Cluster activity
A cluster buy is present: 7 insiders (Lynch Ryan, Brumm Joshua T, Bispham Barbara Harlin, McNeill Jonathan) traded CBIO the same direction within a 7-day window. Shared conviction is a stronger structural signal than a lone trade.
How this compares with CRESCENT BIOPHARMA, INC.'s own history
Open-market buys make up 20% of the 20 scoreable CBIO transactions on record between Dec 4, 2025 and Sep 18, 2026. Comparing a filing with the company's own buy/sell mix is how you tell a routine disposal from an unusual accumulation.
Methodology and sources
Scores come from six published, user-adjustable factors (insider role, cluster activity, trade size versus the insider's own history, position impact, filing urgency, and direct versus indirect ownership). The score describes the filing, not future returns. This is not investment advice.
Key facts
- Scoreable Form 4 transactions on record: 20
- Open-market buys: 4
- Sales: 16
- Distinct insiders: 8
- Strongest recent Greediness Score: 91 (Strong)
Primary sources
Related
- Strongest filing
- CBIO in the live feed
- How the Greediness Score works
- What is a cluster buy?
- Form 4 transaction codes
The score describes the filing, not future returns. This is not investment advice.